dynorphin (1-11) profile

ID Source	ID
PubMed CID	3086114
CHEMBL ID	438223
MeSH ID	M0130212

Synonym
dynorphin a (1-11)
CHEMBL438223 ,
bdbm50040123
[d-pro-10]dyn a-(1-11)
htry-gly-gly-phe-leu-arg-arg-lle-arg-pro-lysoh
tyr-gly-gly-phe-leu-arg-arg-ile-arg-pro-lys
gtpl1618
dynorphin 1-11
dynorphin-(1-11)
dynorphin (1-11)
nh2-tyr-gly-gly-d-trp-leu-arg-arg-d-trp-arg-d-pro-lys-oh
bdbm50019482
alpha-neoendorphin (pig), 7-l-arginine-8-l-isoleucine-8a-endo-l-arginine-
79985-34-5
DTXSID20229978

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Delta-type opioid receptor	Mus musculus (house mouse)	IC50 (µMol)	0.0289	0.0001	0.7298	10.0000	AID226081
Delta-type opioid receptor	Mus musculus (house mouse)	Ki	0.0082	0.0000	0.5393	9.4000	AID439354
Mu-type opioid receptor	Rattus norvegicus (Norway rat)	Ki	0.0035	0.0000	0.3845	8.6000	AID439353
Kappa-type opioid receptor	Rattus norvegicus (Norway rat)	Ki	0.0011	0.0000	0.1868	3.9500	AID439352
Delta-type opioid receptor	Homo sapiens (human)	IC50 (µMol)	0.2840	0.0002	0.7521	8.0140	AID147940
Kappa-type opioid receptor	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	0.2840	0.0003	0.7123	7.0700	AID147940
Kappa-type opioid receptor	Homo sapiens (human)	IC50 (µMol)	0.0066	0.0000	1.2011	10.0000	AID148431; AID1714328
Kappa-type opioid receptor	Homo sapiens (human)	Ki	0.0001	0.0000	0.3624	10.0000	AID1714328
D(1A) dopamine receptor	Sus scrofa (pig)	Ki	0.0035	0.0005	1.2223	8.8000	AID439353
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
immune response	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Delta-type opioid receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
adult locomotory behavior	Delta-type opioid receptor	Homo sapiens (human)
negative regulation of gene expression	Delta-type opioid receptor	Homo sapiens (human)
negative regulation of protein-containing complex assembly	Delta-type opioid receptor	Homo sapiens (human)
positive regulation of CREB transcription factor activity	Delta-type opioid receptor	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Delta-type opioid receptor	Homo sapiens (human)
response to nicotine	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
eating behavior	Delta-type opioid receptor	Homo sapiens (human)
regulation of mitochondrial membrane potential	Delta-type opioid receptor	Homo sapiens (human)
regulation of calcium ion transport	Delta-type opioid receptor	Homo sapiens (human)
cellular response to growth factor stimulus	Delta-type opioid receptor	Homo sapiens (human)
cellular response to hypoxia	Delta-type opioid receptor	Homo sapiens (human)
cellular response to toxic substance	Delta-type opioid receptor	Homo sapiens (human)
neuropeptide signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
immune response	Kappa-type opioid receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
chemical synaptic transmission	Kappa-type opioid receptor	Homo sapiens (human)
sensory perception	Kappa-type opioid receptor	Homo sapiens (human)
locomotory behavior	Kappa-type opioid receptor	Homo sapiens (human)
sensory perception of pain	Kappa-type opioid receptor	Homo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
response to insulin	Kappa-type opioid receptor	Homo sapiens (human)
positive regulation of dopamine secretion	Kappa-type opioid receptor	Homo sapiens (human)
negative regulation of luteinizing hormone secretion	Kappa-type opioid receptor	Homo sapiens (human)
response to nicotine	Kappa-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
maternal behavior	Kappa-type opioid receptor	Homo sapiens (human)
eating behavior	Kappa-type opioid receptor	Homo sapiens (human)
response to estrogen	Kappa-type opioid receptor	Homo sapiens (human)
estrous cycle	Kappa-type opioid receptor	Homo sapiens (human)
response to ethanol	Kappa-type opioid receptor	Homo sapiens (human)
regulation of saliva secretion	Kappa-type opioid receptor	Homo sapiens (human)
behavioral response to cocaine	Kappa-type opioid receptor	Homo sapiens (human)
sensory perception of temperature stimulus	Kappa-type opioid receptor	Homo sapiens (human)
defense response to virus	Kappa-type opioid receptor	Homo sapiens (human)
cellular response to lipopolysaccharide	Kappa-type opioid receptor	Homo sapiens (human)
cellular response to glucose stimulus	Kappa-type opioid receptor	Homo sapiens (human)
positive regulation of p38MAPK cascade	Kappa-type opioid receptor	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Kappa-type opioid receptor	Homo sapiens (human)
response to acrylamide	Kappa-type opioid receptor	Homo sapiens (human)
positive regulation of eating behavior	Kappa-type opioid receptor	Homo sapiens (human)
conditioned place preference	Kappa-type opioid receptor	Homo sapiens (human)
neuropeptide signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
G protein-coupled opioid receptor activity	Delta-type opioid receptor	Homo sapiens (human)
protein binding	Delta-type opioid receptor	Homo sapiens (human)
receptor serine/threonine kinase binding	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled enkephalin receptor activity	Delta-type opioid receptor	Homo sapiens (human)
neuropeptide binding	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor activity	Kappa-type opioid receptor	Homo sapiens (human)
protein binding	Kappa-type opioid receptor	Homo sapiens (human)
receptor serine/threonine kinase binding	Kappa-type opioid receptor	Homo sapiens (human)
dynorphin receptor activity	Kappa-type opioid receptor	Homo sapiens (human)
neuropeptide binding	Kappa-type opioid receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Delta-type opioid receptor	Homo sapiens (human)
synaptic vesicle membrane	Delta-type opioid receptor	Homo sapiens (human)
dendrite membrane	Delta-type opioid receptor	Homo sapiens (human)
presynaptic membrane	Delta-type opioid receptor	Homo sapiens (human)
axon terminus	Delta-type opioid receptor	Homo sapiens (human)
spine apparatus	Delta-type opioid receptor	Homo sapiens (human)
postsynaptic density membrane	Delta-type opioid receptor	Homo sapiens (human)
neuronal dense core vesicle	Delta-type opioid receptor	Homo sapiens (human)
plasma membrane	Delta-type opioid receptor	Homo sapiens (human)
neuron projection	Delta-type opioid receptor	Homo sapiens (human)
nucleoplasm	Kappa-type opioid receptor	Homo sapiens (human)
mitochondrion	Kappa-type opioid receptor	Homo sapiens (human)
cytosol	Kappa-type opioid receptor	Homo sapiens (human)
plasma membrane	Kappa-type opioid receptor	Homo sapiens (human)
membrane	Kappa-type opioid receptor	Homo sapiens (human)
sarcoplasmic reticulum	Kappa-type opioid receptor	Homo sapiens (human)
T-tubule	Kappa-type opioid receptor	Homo sapiens (human)
dendrite	Kappa-type opioid receptor	Homo sapiens (human)
synaptic vesicle membrane	Kappa-type opioid receptor	Homo sapiens (human)
presynaptic membrane	Kappa-type opioid receptor	Homo sapiens (human)
perikaryon	Kappa-type opioid receptor	Homo sapiens (human)
axon terminus	Kappa-type opioid receptor	Homo sapiens (human)
postsynaptic membrane	Kappa-type opioid receptor	Homo sapiens (human)
plasma membrane	Kappa-type opioid receptor	Homo sapiens (human)
neuron projection	Kappa-type opioid receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (35)

Assay ID	Title	Year	Journal	Article
AID1714328	Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay	2016	Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22	Structure-Activity Relationships of [des-Arg
AID149396	Hill coefficient value was measured against delta sites in rat brain homogenates	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis and biological activities of dynorphin A analogues with opioid antagonist properties.
AID77789	The compound was evaluated for the antagonistic activity against dynorphin A in guinea pig ileum.; No observed antagonist effect at concentrations up to 10 uM	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis and biological activities of dynorphin A analogues with opioid antagonist properties.
AID141519	Relative affinity for mu and kappa opioid receptors of guinea pig brain homogenate	1993	Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6	Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs.
AID85659	The compound was evaluated for the antagonistic activity in hamster vas deferens; No observed antagonist effect at concentrations up to 10 uM	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis and biological activities of dynorphin A analogues with opioid antagonist properties.
AID149535	Compound was evaluated for the inhibition of [3H]DSLET([[3H]D-Ser2,Leu5,Thr6]enkephalin binding to Opioid receptor delta 1 in rat brain homogenates.	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis and biological activities of dynorphin A analogues with opioid antagonist properties.
AID1714330	Displacement of [3H]deltorphin-II from human DOR expressed in CHO cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay	2016	Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22	Structure-Activity Relationships of [des-Arg
AID226076	Inhibition of mu-selective antagonist binding to opioid receptor of guinea pig ileum	1993	Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6	Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs.
AID231576	Receptor selectivity index is the ratio of the apparent KI at kappa opioid receptor over the apparent KI at the highest affinity site	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis and biological activities of dynorphin A analogues with opioid antagonist properties.
AID439356	Selectivity ratio of Ki for rat kappa opioid receptor to Ki for mouse delta opioid receptor	2009	Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21	The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues.
AID439353	Displacement of [3H]DAMGO from rat mu opioid receptor expressed in CHO cells	2009	Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21	The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues.
AID226071	Inhibition of [3H]DPDPE binding to delta opioid receptor of guinea pig brain homogenate	1993	Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6	Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs.
AID226073	Inhibition of [3H]U-69593 binding to kappa opioid receptor of guinea pig brain homogenate	1993	Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6	Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs.
AID149847	Selectivity for kappa and mu opioid receptors of guinea pig brain and ileum respectively	1993	Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6	Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs.
AID439354	Displacement of [3H]DPDPE from mouse delta opioid receptor expressed in CHO cells	2009	Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21	The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues.
AID148550	Hill coefficient value was measured against Opioid receptor kappa 1 in guinea pig cerebellum membrane homogenates	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis and biological activities of dynorphin A analogues with opioid antagonist properties.
AID226072	Inhibition of [3H]PL-17 binding to mu opioid receptor of guinea pig brain homogenate	1993	Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6	Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs.
AID231577	Receptor selectivity index is the ratio of the apparent KI at mu opioid receptor over the apparent KI at the highest affinity site	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis and biological activities of dynorphin A analogues with opioid antagonist properties.
AID151295	Hill coefficient value was measured against mu sites in rat brain homogenates	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis and biological activities of dynorphin A analogues with opioid antagonist properties.
AID226081	Inhibition of delta-selective antagonist binding to opioid receptor of mouse vas dferens	1993	Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6	Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs.
AID439352	Displacement of [3H]diprenorphine from rat kappa opioid receptor expressed in CHO cells	2009	Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21	The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues.
AID1714333	Half life in rat plasma by RP-HPLC analysis	2016	Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22	Structure-Activity Relationships of [des-Arg
AID147940	Compound was evaluated for the agonistic activity against Opioid receptor delta 1 in hamster vas deferens.	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis and biological activities of dynorphin A analogues with opioid antagonist properties.
AID148827	Compound was evaluated for the inhibition of [3H]bremazocine binding to Opioid receptor kappa 1 in guinea pig cerebellum membrane homogenates.	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis and biological activities of dynorphin A analogues with opioid antagonist properties.
AID166948	The compound was evaluated for the antagonistic activity in rabbit vas deferens; No observed antagonist effect at concentrations up to 10 uM	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis and biological activities of dynorphin A analogues with opioid antagonist properties.
AID151469	Compound was evaluated for the inhibition of [3H]DAGO([[3H]D-Ala,MePhe4,Glyol5]enkephalin) binding to mu sites in rat brain homogenates.	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis and biological activities of dynorphin A analogues with opioid antagonist properties.
AID231575	Receptor selectivity index is the ratio of the apparent KI at delta opioid receptor over the apparent KI at the highest affinity site	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis and biological activities of dynorphin A analogues with opioid antagonist properties.
AID147934	Relative affinity for delta and kappa opioid receptors of guinea pig brain homogenate	1993	Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6	Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs.
AID1714329	Displacement of [3H]diprenorphine from human MOR expressed in mouse NG108-15 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay	2016	Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22	Structure-Activity Relationships of [des-Arg
AID148431	Compound was evaluated for the agonistic activity against Opioid receptor kappa 1 in rabbit vas deferens.	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis and biological activities of dynorphin A analogues with opioid antagonist properties.
AID149737	Compound was evaluated for the agonistic activity against Opioid receptor mu 1 in guinea pig ileum.	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis and biological activities of dynorphin A analogues with opioid antagonist properties.
AID439355	Selectivity ratio of Ki for rat kappa opioid receptor to Ki for rat mu opioid receptor	2009	Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21	The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues.
AID1346329	Human kappa receptor (Opioid receptors)	1998	NIDA research monograph, Mar, Volume: 178	Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID1346361	Human delta receptor (Opioid receptors)	1998	NIDA research monograph, Mar, Volume: 178	Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID1346364	Human mu receptor (Opioid receptors)	1998	NIDA research monograph, Mar, Volume: 178	Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (22.22)	18.7374
1990's	4 (44.44)	18.2507
2000's	2 (22.22)	29.6817
2010's	1 (11.11)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	9 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
fentanyl Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078). fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.	1.99	1	anilide; monocarboxylic acid amide; piperidines	adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
enkephalin, leucine [no description available]	1.99	1	peptide
etonitazene etonitazene: was heading 1979-94 (see under BENZIMIDAZOLES 1979-90); ETONITAZIN was see ETONITAZENE 1979-94; use BENZIMIDAZOLES to search ETONITAZENE 1979-94; narcotic analgesic similar to morphine in action; used mainly to study narcotic habituation, tolerance, and withdrawal in laboratory animals	1.99	1
levomethadone levomethadone : A 6-(dimethylamino)-4,4-diphenylheptan-3-one that has (R)-configuration. It is the active enantiomer of methadone and its hydrochloride salt is used to treat adults who are addicted to drugs such as heroin and morphine.	1.99	1	6-(dimethylamino)-4,4-diphenylheptan-3-one	antitussive; mu-opioid receptor agonist; NMDA receptor antagonist; opioid analgesic
enkephalin, d-penicillamine (2,5)- Enkephalin, D-Penicillamine (2,5)-: A disulfide opioid pentapeptide that selectively binds to the DELTA OPIOID RECEPTOR. It possesses antinociceptive activity.. DPDPE : A heterodetic cyclic peptide that is a cyclic enkephalin analogue, having D-penicillaminyl residues located at positions 2 and 5, which form the heterocycle via a disulfide bond.	1.99	1	heterodetic cyclic peptide	delta-opioid receptor agonist
u 69593 U 69593: selective ligand for opioid K-receptor. U69593 : A monocarboxylic acid amide obtained by formal condensation between the carboxy group of phenylacetic acid and the secodary amino group of (5R,7S,8S)-N-methyl-7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]decan-8-amine.	1.99	1	monocarboxylic acid amide; N-alkylpyrrolidine; organic heterobicyclic compound; oxaspiro compound	anti-inflammatory agent; diuretic; kappa-opioid receptor agonist
enkephalin, ser(2), leu(5), thr(6)- enkephalin, Ser(2), Leu(5), Thr(6)-: specific probe for the delta-opiate receptor subtype in brain membranes	1.99	1	oligopeptide
quadazocine quadazocine: RN given refers to (2 alpha,6 alpha,11S*)-(+-)-isomer	1.99	1
morphiceptin, n-me-phe(3)- morphiceptin, N-Me-Phe(3)-: RN given refers to D-prolinamide, all L-isomer	1.99	1
pentazocine Pentazocine: The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)	1.99	1	benzazocine
diprenorphine Diprenorphine: A narcotic antagonist similar in action to NALOXONE. It is used to remobilize animals after ETORPHINE neuroleptanalgesia and is considered a specific antagonist to etorphine.	1.99	1	morphinane alkaloid
buprenorphine Buprenorphine: A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.. buprenorphine : A morphinane alkaloid that is 7,8-dihydromorphine 6-O-methyl ether in which positions 6 and 14 are joined by a -CH2CH2- bridge, one of the hydrogens of the N-methyl group is substituted by cyclopropyl, and a hydrogen at position 7 is substituted by a 2-hydroxy-3,3-dimethylbutan-2-yl group. It is highly effective for the treatment of opioid use disorder and is also increasingly being used in the treatment of chronic pain.	1.99	1	morphinane alkaloid	delta-opioid receptor antagonist; kappa-opioid receptor antagonist; mu-opioid receptor agonist; opioid analgesic
arginine vasopressin Arginine Vasopressin: The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.. argipressin : The predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6.	1.98	1	vasopressin	cardiovascular drug; hematologic agent; mitogen
u-50488 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer: A non-peptide, kappa-opioid receptor agonist which has also been found to stimulate the release of adrenocorticotropin (ADRENOCORTICOTROPIC HORMONE) via the release of hypothalamic arginine vasopressin (ARGININE VASOPRESSIN) and CORTICOTROPIN-RELEASING HORMONE. (From J Pharmacol Exp Ther 1997;280(1):416-21). U50488 : A monocarboxylic acid amide obtained by formal condensation between the carboxy group of 3,4-dichlorophenylacetic acid and the secondary amino group of (1R,2R)-N-methyl-2-(pyrrolidin-1-yl)cyclohexanamine	2.69	3	dichlorobenzene; monocarboxylic acid amide; N-alkylpyrrolidine	analgesic; antitussive; calcium channel blocker; diuretic; kappa-opioid receptor agonist
codeine [no description available]	1.99	1	morphinane alkaloid; organic heteropentacyclic compound	antitussive; drug allergen; environmental contaminant; opioid analgesic; opioid receptor agonist; prodrug; xenobiotic
nalmefene nalmefene: RN given refers to 5-alpha isomer	1.99	1	morphinane alkaloid
nalorphine Nalorphine: A narcotic antagonist with some agonist properties. It is an antagonist at mu opioid receptors and an agonist at kappa opioid receptors. Given alone it produces a broad spectrum of unpleasant effects and it is considered to be clinically obsolete.	1.99	1	morphinane alkaloid
naloxone Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.	2.44	2	morphinane alkaloid; organic heteropentacyclic compound; tertiary alcohol	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	1.99	1	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
beta-funaltrexamine beta-funaltrexamine: RN given refers to parent cpd(E)-isomer; structure given in first source	1.99	1	morphinane alkaloid
dihydromorphine Dihydromorphine: A semisynthetic analgesic used in the study of narcotic receptors.	1.99	1	morphinane alkaloid
naltrexone Naltrexone: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.. naltrexone : An organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.	1.99	1	cyclopropanes; morphinane-like compound; organic heteropentacyclic compound	antidote to opioid poisoning; central nervous system depressant; environmental contaminant; mu-opioid receptor antagonist; xenobiotic
enkephalin, ala(2)-mephe(4)-gly(5)- [no description available]	1.99	1	peptide
normorphine normorphine: RN given refers to (5 alpha,6 alpha)-isomer	1.99	1	morphinane alkaloid
norbinaltorphimine norbinaltorphimine: kappa opiate receptor antagonist; structure given in first source	1.99	1	isoquinolines
naltrindole benzofuran naltrindole benzofuran: structure given in first source	1.99	1	morphinane alkaloid
naltrindole naltrindole: delta opioid receptor antagonist	1.99	1	isoquinolines
naloxone benzoylhydrazone naloxone benzoylhydrazone: structure given in first source	1.99	1
7-benzylidenenaltrexone [no description available]	1.99	1
enkephalin, leucine-2-alanine Enkephalin, Leucine-2-Alanine: A delta-selective opioid (ANALGESICS, OPIOID). It can cause transient depression of mean arterial blood pressure and heart rate.	1.99	1
dynorphin (1-17) [no description available]	1.99	1
dynorphin a (1-11)-amide [no description available]	2.48	2
deltorphin ii, ala(2)- [no description available]	1.99	1
dynorphins Dynorphins: A class of opioid peptides including dynorphin A, dynorphin B, and smaller fragments of these peptides. Dynorphins prefer kappa-opioid receptors (RECEPTORS, OPIOID, KAPPA) and have been shown to play a role as central nervous system transmitters.	2.9	4
beta-endorphin beta-Endorphin: A 31-amino acid peptide that is the C-terminal fragment of BETA-LIPOTROPIN. It acts on OPIOID RECEPTORS and is an analgesic. Its first four amino acids at the N-terminal are identical to the tetrapeptide sequence of METHIONINE ENKEPHALIN and LEUCINE ENKEPHALIN.. beta-endorphin : A polypeptide consisting of 31 amino acid residues in the sequence Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu. It is an endogenous opioid peptide neurotransmitter found in the neurons of both the central and peripheral nervous system and results from processing of the precursor protein proopiomelanocortin (POMC).	1.99	1
dynorphin (1-17) [no description available]	1.98	1
rimorphin rimorphin: tridecapeptide NH2-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr-COOH from bovine posterior pituitary gland; major leucine enkephalin containing peptide in tissue that contains dynorphin & alpha-neo-endorphin	1.99	1
dynorphins dynorphin (1-13): potent opioid peptide; see also record for dynorphin & D-Ala(2)-dynorphin (1-11)	2.7	3

Condition	Relationship Strength	Studies
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	2.39	2
Chemical Dependence [description not available]	1.99	1
Addiction, Opioid [description not available]	1.99	1
Opioid-Related Disorders Disorders related to or resulting from abuse or misuse of OPIOIDS.	1.99	1
Substance-Related Disorders Disorders related to substance use or abuse.	1.99	1
Ache [description not available]	2.13	1
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	2.13	1

dynorphin (1-11)

Cross-References

Synonyms (15)

Protein Targets (7)

Inhibition Measurements

Biological Processes (42)

Molecular Functions (6)

Ceullar Components (18)

Bioassays (35)

Research

Studies (9)

Market Indicators

Research Demand Index: 12.16

Study Types

dynorphin (1-11)

Cross-References

Synonyms (15)

Protein Targets (7)

Inhibition Measurements

Biological Processes (42)

Molecular Functions (6)

Ceullar Components (18)

Bioassays (35)

Research

Studies (9)

Market Indicators

Research Demand Index: 12.16

Study Types

Related Drugs (38)

Related Conditions (7)